Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org

October 2008

 



Thursday, October 16, 2008
Humacyte, Inc.

Followed by networking, refreshments & wine bar

The Yale BioHaven Entrepreneurship Series features presentations designed to showcase regionally developed life science technologies that have progressed along the path to commercialization.  Speakers at the BioHaven events represent both the scientific and business side of the enterprises.

The programs focus on key success factors of each company, scientific or technological advantage, business model, and lessons learned in starting and developing the business. The series also provides social networking opportunities for scientists/researchers in the Yale community.  

Humacyte, Inc. will present on October 16, 2008.

Humacyte's core technology is the engineering of human-based tissue scaffolds that can be shaped into tubes, sheets, or particulate conformations and can be applied to many specific applications. The Company's process includes growing these scaffolds utilizing a proprietary process with a unique cell source. The process results in the creation of an off-the-shelf product that can be utilized in any patient. 

Humacyte is developing its technology for multiple product opportunities. Markets to be addressed include: cardiovascular, cosmetic, and soft tissue reconstruction. At present the company is primarily focused on developing its products for vascular replacement and as a dermal filler.

With the injectable formulation, there are several different markets that can be addressed. For instance, an injectable product can be used as a dermal filler in the cosmetics market or as a bulking agent in the urological markets. 

In its tubular conformation, the product can be used for general vascular replacements in the periphery and in kidney failure patients who require graft placement for dialysis machine access. The longer term and broadest potential market for Humacyte's technology is the coronary artery bypass
(CABG) market.

Speakers

Geoffrey Erickson, Ph.D.

President and CEO, Humacyte, Inc.

Laura Niklason, M.D., Ph.D.

Founder and CSO, Humacyte, Inc. Associate Professor of Anesthesia and Biomedical Engineering, Yale University

Thursday, October 16, 2008
3:30 P.M. Registration
4:00 P.M. Seminar
5:00 P.M. Networking, Refreshments & Wine Bar

Location
The Anlyan Center auditorium, Yale Medical School.

Directions & Parking:
http://info.med.yale.edu/maps/cab.html

RSVP
Registration is free, but please RSVP in advance. E-mail to biohaven@yale.edu or call the Yale OCR main number: 203-785-6209.

Lead sponsors: Wiggin and Dana and PricewaterhouseCoopers.
 

 

Also sponsored by Elm Street Ventures.


Presented by CURE and the Yale Office of Cooperative Research.


Additional support from the Yale Entrepreneurial Institute and the Yale Biotechnology & Pharmaceutical Society.


 

 
 
Copyright © 2008 Connecticut United for Research Excellence. All rights reserved.
Visit CURE at http://curenet.org and BioBus Educational Programs at http://ctbiobus.org
Newsletter developed and edited by
HarveyMalis Communications LLC, Guilford, Conn.